Asciminib is an allosteric inhibitor targeting breakpoint cluster region-abelson murine leukemia 1 (BCR-ABL1) kinase activity that has gained approval for treating patients diagnosed with chronic-phase chronic myeloid leukemia (CML) who have not responded to two prior lines of therapy or for those carrying the T315I mutation [4]. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.